



ASX Announcement and Media Release

(ASX:SIE)

## RESULTS OF ANNUAL GENERAL MEETING

Wednesday 30 June 2010

SciGen Ltd wishes to advise that all resolutions contained in the Notice of Annual General Meeting were duly voted on in accordance with Section 251 AA of the Corporations Act 2001 and ASX Listing Rule 3.13.2

The following information is provided in relation to the resolutions considered by shareholders at the Annual General Meeting held on 30 June 2010 at 9.30am in Singapore.

RESOLUTION	DESCRIPTION	FOR	AGAINST	ABSTAIN	NO INSTRUCTION	RESULT
1	Adoption of the Audited Accounts - 31 December 2009	500,315,241	240	-	-	CARRIED
2	Re-election of Mr Kenneth Gross	500,315,241	240	-	-	CARRIED
3	Re-election of Dr Marian Gorecki	500,315,241	240	-	-	CARRIED
4	Re-election of Dr Joanna Szymanska-Bulska	500,315,241	240	-	-	CARRIED
5	Re-election of Mr Ryszard Krauze	500,309,641	5,840	-	-	CARRIED
6	Re-election of Mr Mateusz Kosecki	500,309,641	5,840	-	-	CARRIED
7	Re-election of Mr Amol Shah	500,309,283	6,198	-	-	CARRIED
8	Re-election of Mr Martin Cooper	500,315,241	240	-	-	CARRIED
9	Re-election of Ms Jenny Low	500,315,241	240	-	-	CARRIED
10	Appointment of Auditors	500,315,481	-	-	-	CARRIED
11	Approval of Directors Remuneration - 31 December 2009	500,300,983	11,498	-	3,000	CARRIED
12	Authority to Allot & Issue Shares pursuant to Section 161 of the Companies (Amendment) Act 2004, Singapore	500,303,983	11,498	-	-	CARRIED
13	Approval of disposal of part of the Company's Interest in SciGen BioPharma Pvt. Ltd.	500,301,136	10,345	-	-	CARRIED

## About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

<b>For further information:</b> Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638